drugset / Trial / NCT04156217
EBV-TCR-T Cells for EB Virus Infection After HSCT
Phase 1
Completed
18 enrolled
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of EBV-TCR-T cells in patients with EB virus infection after HSCT.
Timeline
- Start
- 2020-02-10
- Primary completion
- 2021-07-30
- Completion
- 2021-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EBV-TCR-T cells | Cell therapy | 100000 cells | Intravenous |
| Subject | EBV-TCR-T cells | Cell therapy | 1e+06 cells | Intravenous |